Flag of the European Union EU Clinical Trials Register Help

Clinical trials for No treatment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34,471 result(s) found for: No treatment. Displaying page 598 of 1,724.
    «« First « Previous 594  595  596  597  598  599  600  601  602  Next» Last»»
    EudraCT Number: 2006-002922-51 Sponsor Protocol Number: H6D-MC-LVGH Start Date*: 2006-10-16
    Sponsor Name:Lilly ICOS LLC
    Full Title: Tadalafil 5 mg Once a Day Compared to Placebo in Improving Erectile Dysfunction and Sexual Quality of Life
    Medical condition: Erectile Dysfunction
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061461 Erectile dysfunction LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-015755-24 Sponsor Protocol Number: NN1250-3644 Start Date*: 2010-04-08
    Sponsor Name:Novo Nordisk A/S
    Full Title: An extension trial to trial NN1250-3583 comparing safety and efficacy of NN1250 with insulin glargine, both with insulin aspart as meal-time insulin, in type 1 diabetes
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067584 Type 1 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000685-36 Sponsor Protocol Number: EMR 200025 – 001 Start Date*: 2006-11-29
    Sponsor Name:Merck KGaA
    Full Title: A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX-4 plus cetuximab versus UFOX plus cetuximab as first-line therapy in subjects with metastatic colorectal cancer
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FR (Completed) BE (Completed) GR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000082-38 Sponsor Protocol Number: HUM05-019 Start Date*: 2007-05-24
    Sponsor Name:Aarhus University Hospital, Denmark
    Full Title: The OPERA Study. Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid...
    Medical condition: In early RA methotrexate and intra-articular glucocorticoid in combination with adalimumab is better than methotrexate and intra-articular glucocorticoid in achieving control of the disease as asse...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-021955-14 Sponsor Protocol Number: BUP3030 Start Date*: 2011-10-17
    Sponsor Name:Purdue Pharma L.P.
    Full Title: A Multicenter, Inpatient, Open-label Study to Characterize the Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Aged from Birth to 6 Years of Age...
    Medical condition: Acute moderate to severe pain requiring opioids for at least 24 hours in postoperative and prolonged endotracheal intubated patients
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10002182 Analgesia LLT
    14.0 10042613 - Surgical and medical procedures 10021415 Immediate postoperative analgesia LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001052-18 Sponsor Protocol Number: 010 Start Date*: 2020-03-25
    Sponsor Name:Regents of the University of Minnesota
    Full Title: A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European U...
    Medical condition: Influenza COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) DE (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-017740-13 Sponsor Protocol Number: KGR03-P03 Start Date*: 2010-02-25
    Sponsor Name:PHF SA
    Full Title: Pilot study to evaluate the efficacy, safety and tolerability of ammonium chloride in terms of protection from hepatotoxic effect of Hep C infection and normalisation of altered liver parameters, i...
    Medical condition: Hepatitis C virus infected relapsed male and female patients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002550-32 Sponsor Protocol Number: VIPES Start Date*: 2012-12-21
    Sponsor Name:DBV Technologies SA
    Full Title: A double-blind, placebo-controlled, randomized trial to study the Viaskin® Peanut’s Efficacy and Safety for treating peanut allergy in children and adults.
    Medical condition: Treatment of peanut allergy in adults and children age 6 years and older with documented hypersensitivity to peanut. The induction of clinical desensitization to peanut in patients allergic to pean...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005566-33 Sponsor Protocol Number: CV185-398Wakili Start Date*: 2016-06-14
    Sponsor Name:Klinikum der Universitaet Muenchen AoeR
    Full Title: APixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF)
    Medical condition: Patients with acute coronary syndrome and atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000454-38 Sponsor Protocol Number: CPDR001X2201 Start Date*: 2015-10-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progr...
    Medical condition: Moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-003442-33 Sponsor Protocol Number: D8480C00038 Start Date*: 2005-11-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Factorial, Double-blind Study to Investigate the Management of AZD2171-induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients with Advanced Sol...
    Medical condition: Management of AZD2171-induced hypertension in patients with advanced solid tumours
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005147-28 Sponsor Protocol Number: WA20494 Start Date*: 2007-07-25
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methot...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) FR (Completed) AT (Completed) GR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001921-34 Sponsor Protocol Number: C31001 Start Date*: 2015-04-30
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Bre...
    Medical condition: ER+/HER2- Advanced or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003062-13 Sponsor Protocol Number: AZP01-CLI-003 Start Date*: 2020-02-25
    Sponsor Name:Millendo Therapeutics SAS
    Full Title: A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndrome
    Medical condition: Prader-Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002551-22 Sponsor Protocol Number: HZA114971 Start Date*: 2017-02-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg once dai...
    Medical condition: Paediatric Subjects with Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-005175-16 Sponsor Protocol Number: SG/0021 Start Date*: 2006-07-20
    Sponsor Name:HAL Allergy BV
    Full Title: Twin SUBLIVAC® Grasses Clinical Efficay Study
    Medical condition: IgE mediated allergic disorders triggered by grass pollen
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003164-21 Sponsor Protocol Number: 652-2-203 Start Date*: 2015-01-05
    Sponsor Name:Tobira Therapeutics, Inc., a subsidiary of Allergan plc
    Full Title: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis
    Medical condition: Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002005-36 Sponsor Protocol Number: RM-493-015 Start Date*: 2017-10-30
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Leptin Receptor (LEPR) Deficiency...
    Medical condition: Early Onset Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003470-17 Sponsor Protocol Number: KKL172014 Start Date*: Information not available in EudraCT
    Sponsor Name:Krka, d.d. Novo mesto
    Full Title: The efficacy and safety of olmesartan medoxomil/amlodipine fixed combination in patients with grade 1 to grade 2 arterial hypertension. An international randomized, double-blind, 10-week multi-fact...
    Medical condition: Primary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004866 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-006309-17 Sponsor Protocol Number: A7-14. Start Date*: 2009-11-19
    Sponsor Name:KONSTANTINAS POVILAS VALUCKAS, INSTITUTE OF ONCOLOGY OF VILNIUS UNIVERSITY
    Full Title: Significance of prognostic and predictive factors for the efficacy and safety of neoadjuvant chemotherapy in combination with chemoradiation administered in patients with locally advanced cervical ...
    Medical condition: Locally advanced IIB-IIIB stages cervical cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008229 Cervical cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: LT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 594  595  596  597  598  599  600  601  602  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Feb 15 16:55:42 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA